Evidence map›Paper›PMID 40012283›Full record

ReviewCurrent cardiology reviews2025

Umbilical Cord Matrix (Wharton Jelly) Mesenchymal Stem Cells in Next-generation Myocardial Repair and Regeneration: Mechanisms and Pre-clinical Evidence.

Ewa Kwiecien, Marta Kot, Lukasz Czyz, Leszek Drabik, Adam Mazurek, Martyna Sikorska, Maciej Skubera, Lukasz Tekieli, Marcin Majka, Piotr Musialek

Abstract readReview
In one paragraph

Review in Current cardiology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ewa KwiecienDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Marta KotDepartment of Transplantation, Faculty of Medicine, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
Lukasz CzyzDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Leszek DrabikDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Adam MazurekDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Martyna SikorskaDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Maciej SkuberaDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Lukasz TekieliDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.
Marcin MajkaDepartment of Transplantation, Faculty of Medicine, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
Piotr MusialekDepartment of Cardiac & Vascular Diseases, St. John Paul II Hospital, Jagiellonian University, Krakow, Poland.

Funding

"CIRCULATE" STRATEGMED, National Centre for Research and Development, Poland 265761Jagiellonian University Medical College and Ministry of Science and Higher Education, Poland K/ZDS/005644, N41/DBS/001103
6 · The paper itself

Abstract

Chronic ischemic heart failure (CIHF), caused by myocardial injury and cell loss, is a growing public health concern. Despite substantial investments in pharmaco- and device therapies for acute myocardial infarction and CIHF over the past decades, long-term prognosis has shown little improvement. There is a clear need to develop novel therapeutic strategies capable of attenuating progression from acute to chronic myocardial damage, reducing adverse myocardial remodeling, and enhancing myocardial contractility. Cell-based approaches are an important direction in basic and clinical research. Nevertheless, candidate cell types tested to-date in experimental and human studies show several fundamental limitations, including insufficient quantities and potency, poor myocardial uptake, immunogenicity and/or risk of tumorigenicity. Human umbilical cord matrix is a rich source of mesenchymal stem cells (Wharton's jelly mesenchymal stem cells, WJMSCs). WJMSCs are naturally low-immunogenic, demonstrate high plasticity and proliferation capacity, and exhibit an absence of tumorigenic potential. Moreover, by producing specific anti-inflammatory cytokines and chemokines, they reduce the inflammatory response (hence their use in graft-

Indexed as

Heart FailureMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMyocardial InfarctionRegenerationUmbilical CordWharton JellyAnimalsHumansacute myocardial infarction (AMI)advanced therapy medicinal product (ATMP).animal models of human diseasechronic ischemic heart failure (CIHF)myocardial regenerationmyocardial repairstem cellsumbilical cordWharton’s Jelly mesenchymal stem cells (WJMSCs)

Identifiers

PMID40012283
PMCPMC12307995

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.